Armed with $55M in Third Rock cash, Goldfinch Bio sets out to build a kidney disease pipeline
Three years ago, Peter Mundel at Harvard Medical School published an intriguing study in the New England Journal of Medicine that highlighted the promise of abatacept in treating a threatening kidney disease. Like many in the field, he was looking for ways to adapt existing drugs to fight kidney disease.
Now, though, Mundel has shut down his lab at Harvard and joined a Third Rock startup that is coming out of stealth mode today. But instead of adapting old drugs for kidney disease, the goal is to develop a pipeline of novel therapies, armed with new insights into the genetics of what triggers these ailments, and how they can be treated.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.